Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant.

ABSTRACT:

Purpose

Germline CHEK2 c.1100delC-associated breast cancer (BC) patients have been reported with worse prognosis than patients without the variant. However, results are based on older cohorts and treatment regimens. As part of the Hebon-CHEK2 study, we aim to study prognosis in a Dutch cohort of genetically tested ER-positive BC patients diagnosed from 2006 onwards.

Methods

All patients underwent genetic testing based on personal and family history risk, and data on BC outcomes were collected. Hazard ratios (HRs) and 95 % confidence intervals (CI) for the association of CHEK2-status with prognosis were estimated via delayed entry Cox regression models, adjusted for age and year of diagnosis, tumor size, nodal status, and primary treatment regimens. Furthermore, we meta-analy

SUBMITTER: Schreurs MAC 

PROVIDER: S-EPMC12702395 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature